Allied Market Research
Loading...
0
New
New
2022
Oral Cancer Treatment Market

Oral Cancer Treatment Market by Treatment (Chemotherapy, Immunotherapy, and Targeted Therapy), Age Group (30-49, 50-69 and 70<), and End User (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Store): Global Opportunity Analysis and Industry Forecast, 2021–2030

A14903
Pages: 213
Dec 2021 | 537 Views
   
Author(s) : Smita Nerkar , Onkar Sumant
Tables: 111
Charts: 43
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Oral Cancer Treatment Market

Request Now !

Global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.

Oral cancer includes cancers of the mouth and the back of the throat. Oral cancers develop on the tongue, the tissue lining the mouth and gums, under the tongue, at the Oral Cancer Treatment Market base of the tongue, and the area of the throat at the back of the mouth. Furthermore, oral cancer accounts for approximately 3% of all cancers diagnosed annually in the U.S, or about 53,000 new cases each year. In addition, oral cancer most often occurs in people over the age of 40 and affects more than twice as many men as women. Most oral cancers are related to tobacco use, alcohol use (or both), or infection by the human papilloma virus (HPV).

Oral-Cancer-Treatment-Market--2021-2030

Get more information on this report : Request Sample Pages

Increase in demand for targeted mode of therapies, surge in the R&D activities for the development of novel drugs and therapies, high unmet need of treatment and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of oral cancer treatment market. Further, growing prevalence of oral or mouth cancer globally is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure, growing consumption of tobacco products such as cigarettes, cigars, pipes and chewing tobacco and upsurge in the special designation from regulatory authorities are other factors also raising the growth of the market. On the other hand, increasing personal disposable income coupled with rising prevalence of papillomavirus infection is other indirect cause that is expected to create lucrative growth opportunities for the market.

However, lack of awareness about oral cancer in the backward and underdeveloped areas will hamper the market growth. 

The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. Moreover, COVID-19 has positively impacted the oral cancer treatment market. When COVID-19 was first identified, many researchers redirected their focus to the study of this novel virus and the disease it causes. Severe COVID‐19 represents viral pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, which leads to acute respiratory distress syndrome. Its appearances can be viewed as a combination of the two processes that is viral pneumonia and acute respiratory distress syndrome. SARS‐CoV‐2 represents an ongoing worldwide threat, as this virus family has the potential to mutate and infect non‐immune population. Furthermore, Owing to the well-known major risk factors, oral cancer is considered a preventable disease and moreover, due to easy accessibility, it can be detected in early stages. Yet, majority of oral cancer cases in the developing countries are diagnosed in advanced stages, resulting in increased morbidity and mortality of oral cancer. Generally, dentists play a pivotal role in the early detection of oral cancer through opportunistic screening when a patient presents in a dental practice for routine care and by rapid referral of suspicious lesions. In the time of COVID-19, nevertheless, the whole world being in lockdown, and dental clinics are closed. Therefore, opportunities for screening the oral cavity might be significantly disrupted, and consequently diagnosis of malignant and/or potentially malignant lesions might be delayed, a matter that inevitably leads to a missed diagnosis of oral cancer or, at best, diagnosis later on but at a late stage.

Oral Cancer Treatment Market
By Drug Therapy

Your browser does not support the canvas element.

Chemotherapy segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Oral Cancer Treatment Market Segmentation  

The global oral cancer treatment market is segmented into drug type, age group, distribution channel, and region. Depending on treatment, the market is bifurcated into chemotherapy, immunotherapy, targeted therapy. The age group segment is further categorized into 30-49, 50-69 and 70<. By end user, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, online stores. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

On the basis of treatment, the radiation therapy segment was the major shareholder 2020. In oral cancer, it's usually used after surgery to prevent the cancer returning.

In throat cancer, it's often the first treatment to be given, in combination with chemotherapy medicine (chemoradiotherapy). The treatment is usually given every day over the course of 6 weeks, depending on the size of the cancer and how far it has spread.

Oral Cancer Treatment Market
By Distribution Channel

Your browser does not support the canvas element.

Hospital Pharmacies segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of North America Oral Cancer Treatment Market  

Increase in demand for surgical therapies for the treatment of oral cancer and rise in investment by governments in research & development to improve treatments boost the global market. North America dominated the global market in 2020 and this trend is projected to continue during the forecast period owing to the rising health care investments in the region and prevalence of oral cancer. The oral cancer treatment market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. Rise in tobacco usage, increase in smoking, rapidly expanding health care industry, growing patient population, and high unmet needs are likely to drive the oral cancer treatment market in the region. Further, favorable government policies and rise in disposal income are anticipated to propel the oral cancer treatment market in the region during the forecast period.

The key market players profiled in the report include Bristol-Myers Squibb Company Cipla Inc., Eli-Lilly, F. Hoffmann-La Roche    , Fresenius Kabi AG, Intas Pharmaceuticals Ltd, Merck & Co., Inc., Sanofi, Teva Pharmaceuticals Industries Ltd and Viatris Inc.

Oral Cancer Treatment Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 5.4% during 2021-2030.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global oral cancer treatment market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products the market used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Market Segments

  • By Treatment
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
  • By Age Group
    • 30-49
    • 50-69
    • 70<
  • By End User
    • Hospital Pharmacies
    • Drug Stores & Retail Pharmacies
    • Online Stores
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in prevalence of oral cancer
3.5.1.2.Surge in global geriatric population
3.5.1.3.Increase in government expenditure on healthcare

3.5.2.Restraint

3.5.2.1.Adverse effects associated with the use cancer drugs

3.5.3.Opportunities

3.5.3.1.High growth potential in untapped emerging economies
3.5.3.2.Increase in number of pipeline drugs

3.5.4.Impact analysis

3.6.COVID-19 impact analysis on the oral cancer treatment market

CHAPTER 4:ORAL CANCER TREATMENT MARKET, BY DRUG TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Chemotherapy

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Immunotherapy

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Targeted therapy

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

CHAPTER 5:ORAL CANCER TREATMENT MARKET, BY AGE GROUP

5.1.Overview

5.1.1.Market size and forecast

5.2.30-49

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.50-69

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.70<

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:ORAL CANCER TREATMENT MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospital Pharmacies

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Drug Stores & Retail Pharmacies

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Online Stores

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:ORAL CANCER TREATMENT MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S. oral cancer treatment market, by drug type
7.2.2.2.U.S. oral cancer treatment market, by age group
7.2.2.3.U.S. oral cancer treatment market, by distribution channel
7.2.2.4.Canada oral cancer treatment market, by drug type
7.2.2.5.Canada oral cancer treatment market, by age group
7.2.2.6.Canada oral cancer treatment market, by distribution channel
7.2.2.7.Mexico oral cancer treatment market, by drug type
7.2.2.8.Mexico oral cancer treatment market, by age group
7.2.2.9.Mexico oral cancer treatment market, by distribution channel

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany oral cancer treatment market, by drug type
7.3.2.2.Germany oral cancer treatment market, by age group
7.3.2.3.Germany oral cancer treatment market, by distribution channel
7.3.2.4.France oral cancer treatment market, by drug type
7.3.2.5.France oral cancer treatment market, by age group
7.3.2.6.France oral cancer treatment market, by distribution channel
7.3.2.7.UK oral cancer treatment market, by drug type
7.3.2.8.UK oral cancer treatment market, by age group
7.3.2.9.UK oral cancer treatment market, by distribution channel
7.3.2.10.Italy oral cancer treatment market, by drug type
7.3.2.11.Italy oral cancer treatment market, by age group
7.3.2.12.Italy oral cancer treatment market, by distribution channel
7.3.2.13.Spain oral cancer treatment market, by drug type
7.3.2.14.Spain oral cancer treatment market, by age group
7.3.2.15.Spain oral cancer treatment market, by distribution channel
7.3.2.16.Rest of Europe oral cancer treatment market, by drug type
7.3.2.17.Rest of Europe oral cancer treatment market, by age group
7.3.2.18.Rest of Europe oral cancer treatment market, by distribution channel

7.3.3.Europe oral cancer treatment market, by drug type
7.3.4.Europe oral cancer treatment market, by age group
7.3.5.Europe oral cancer treatment market, by distribution channel

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan oral cancer treatment market, by drug type
7.4.2.2.Japan oral cancer treatment market, by age group
7.4.2.3.Japan oral cancer treatment market, by distribution channel
7.4.2.4.China oral cancer treatment market, by drug type
7.4.2.5.China oral cancer treatment market, by age group
7.4.2.6.China oral cancer treatment market, by distribution channel
7.4.2.7.Australia oral cancer treatment market, by drug type
7.4.2.8.Australia oral cancer treatment market, by age group
7.4.2.9.Australia oral cancer treatment market, by distribution channel
7.4.2.10.India oral cancer treatment market, by drug type
7.4.2.11.India oral cancer treatment market, by age group
7.4.2.12.India oral cancer treatment market, by distribution channel
7.4.2.13.South Korea oral cancer treatment market, by drug type
7.4.2.14.South Korea oral cancer treatment market, by age group
7.4.2.15.South Korea oral cancer treatment market, by distribution channel
7.4.2.16.Rest of Asia-Pacific oral cancer treatment market, by drug type
7.4.2.17.Rest of Asia-Pacific oral cancer treatment market, by age group
7.4.2.18.Rest of Asia-Pacific oral cancer treatment market, by distribution channel

7.4.3.Asia-Pacific oral cancer treatment market, by drug type
7.4.4.Asia-Pacific oral cancer treatment market, by age group
7.4.5.Asia-Pacific oral cancer treatment market, by distribution channel

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil oral cancer treatment market, by drug type
7.5.2.2.Brazil oral cancer treatment market, by age group
7.5.2.3.Brazil oral cancer treatment market, by distribution channel
7.5.2.4.Saudi Arabia oral cancer treatment market, by drug type
7.5.2.5.Saudi Arabia oral cancer treatment market, by age group
7.5.2.6.Saudi Arabia oral cancer treatment market, by distribution channel
7.5.2.7.South Africa oral cancer treatment market, by drug type
7.5.2.8.South Africa oral cancer treatment market, by age group
7.5.2.9.South Africa oral cancer treatment market, by distribution channel
7.5.2.10.Rest of LAMEA oral cancer treatment market, by drug type
7.5.2.11.Rest of LAMEA oral cancer treatment market, by age group
7.5.2.12.Rest of LAMEA oral cancer treatment market, by distribution channel

7.5.3.LAMEA oral cancer treatment market, by drug type
7.5.4.LAMEA oral cancer treatment market, by age group
7.5.5.LAMEA oral cancer treatment market, by distribution channel

CHAPTER 8:COMPANY PROFILES

8.1.BRISTOL MAYERS SQUIBB COMPANY

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.CIPLA INC.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.ELI-LILLY

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.F-HOFFMANN-LA-ROCHE

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.FRESENIUS KABI AG

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.INTAS PHARMACEUTICALS LTD.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio

8.7.MERCK & CO. INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.SANOFI S.A

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.TEVA PHARMACEUTICALS INDUSTRIES LTD

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product Portfolio
8.9.5.Business performance

8.10.VIATRIS INC. (MYLAN N.V)

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product Portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 02.CHEMOTHERAPY ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.IMMUNOTHERAPY ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04.TARGETED THERAPY ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 06.30-49 ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07.50-69 CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 08.70< CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 09.ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 10.ORAL CANCER TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2020-2030 ($MILLION)
TABLE 11.ORAL CANCER TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
TABLE 12.ORAL CANCER TREATMENT MARKET FOR ONLINE STORES, BY REGION, 2020-2030 ($MILLION)
TABLE 13.ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14.NORTH AMERICA ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15.U.S. ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 16.U.S. ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 17.U.S. ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 18.CANADA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 19.CANADA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 20.CANADA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 21.MEXICO ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 22.MEXICO ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 23.MEXICO ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 24.EUROPE ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 25.GERMANY ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 26.GERMANY ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 27.GERMANY ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 28.FRANCE ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 29.FRANCE ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 30.FRANCE ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 31.UK ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 32.UKORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 33.UK ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 34.ITALY ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 35.ITALY ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 36.ITALY ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 37.SPAIN ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 38.SPAIN ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 39.SPAIN ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 40.REST OF EUROPE ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 41.REST OF EUROPE ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 42.REST OF EUROPE ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 43.EUROPE ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 44.EUROPE ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 45.EUROPE ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 46.ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 47.JAPAN ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 48.JAPAN ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 49.JAPAN ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 50.CHINA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 51.CHINA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 52.CHINA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 53.AUSTRALIA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 54.AUSTRALIA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 55.AUSTRALIA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 56.INDIA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 57.INDIA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 58.INDIA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 59.SOUTH KOREA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 60.SOUTH KOREA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 61.SOUTH KOREA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 62.REST OF ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 63.REST OF ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 64.REST OF ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 65.ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 66.ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 67.ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 68.LAMEA ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 69.BRAZIL ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 70.BRAZIL ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 71.BRAZIL ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 72.SAUDI ARABIA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 73.SAUDI ARABIA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 74.SAUDI ARABIA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 75.SOUTH AFRICA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 76.SOUTH AFRICA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 77.SOUTH AFRICA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 78.REST OF LAMEA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 79.REST OF LAMEA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 80.REST OF LAMEA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 81.LAMEA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020–2030
TABLE 82.LAMEA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020–2030
TABLE 83.LAMEA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030
TABLE 84.BMS: COMPANY SNAPSHOT
TABLE 85.BMS: PRODUCT PORTFOLIO
TABLE 86.CIPLA:COMPANY SNAPSHOT
TABLE 87.CIPLA: OPERATING SEGMENTS
TABLE 88.CIPLA: PRODUCT PORTFOLIO
TABLE 89.LILLY:COMPANY SNAPSHOT
TABLE 90.LILLY: OPERATING SEGMENTS
TABLE 91.LILLY: PRODUCT PORTFOLIO
TABLE 92.ROCHE: COMPANY SNAPSHOT
TABLE 93.ROCHE: OPERATING SEGMENTS
TABLE 94.ROCHE: PRODUCT PORTFOLIO
TABLE 95.FRESENIUS: COMPANY SNAPSHOT
TABLE 96.FRESENIUS: OPERATING SEGMENTS
TABLE 97.FRESENEUS: PRODUCT PORTFOLIO
TABLE 98.INTAS: COMPANY SNAPSHOT
TABLE 99.INTAS: PRODUCT PORTFOLIO
TABLE 100.MERCK: COMPANY SNAPSHOT
TABLE 101.MERCK: OPERATING SEGMENTS
TABLE 102.MERCK: PRODUCT PORTFOLIO
TABLE 103.SANOFI: COMPANY SNAPSHOT
TABLE 104.SANOFI: OPERATING SEGMENTS
TABLE 105.SANOFI: PRODUCT PORTFOLIO
TABLE 106.TEVA: COMPANY SNAPSHOT
TABLE 107.TEVA : OPERATING SEGMENTS
TABLE 108.TEVA: PRODUCT PORTFOLIO
TABLE 109.VIATRIS: COMPANY SNAPSHOT
TABLE 110.VIATRIS : OPERATING SEGMENTS
TABLE 111.VIATRIS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.ORAL CANCER TREATMENT MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021 (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF 30-49 ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF 50-69ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF 70< ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF ORAL CANCER TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF ORAL CANCER TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF ORAL CANCER TREATMENT MARKET FOR ONLINE STORES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.BMS: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.BMS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 24.CIPLA: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.CIPLA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.CIPLA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27.LILLY :NET SALES 2018- 2020 ($MILLION)
FIGURE 28.LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.MERCK REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.MERCK REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.SANOFI: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.TEVA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 41.VIATRIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.VIATRIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.VIATRIS: REVENUE SHARE BY REGION, 2020 (%)

 
 

Oral cancer includes cancers of the mouth and the back of the throat. Oral cancers develop on the tongue, the tissue lining the mouth and gums, under the tongue, at the base of the tongue, and the area of the throat at the back of the mouth. Furthermore, oral cancer accounts for roughly 3% of all cancers diagnosed annually in the U.S, or about 53,000 new cases each year.

Growing prevalence of oral or mouth cancer globally is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure, growing consumption of tobacco products such as cigarettes, cigars, pipes and chewing tobacco and upsurge in the special designation from regulatory authorities are other factors also raisingfueling the growth of the market. On the other hand, increasing personal disposable income coupled with rising prevalence of papillomavirus infection is other indirect cause that will create lucrative growth opportunities for the market. However, lack of awareness about the oral cancer in the backward and underdeveloped areas will hamper the market growth.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Oral Cancer Treatment Market is $1,579.47 million in 2020.

A. The forcast period for Oral Cancer Treatment Market is 2021 to 2030

A. The market value of Oral Cancer Treatment Market in 2021 is $5,893.53 million.

A. The base year is 2020 in Oral Cancer Treatment Market

A. Top companies such as Apeptico Forschung Und Entwicklung GmBH, Bayer AG, General Electric Company, Glaxosmithkline Plc, Koninklijke Philips N.V., Linde Plc., Medtronic Plc., Ony Biotech Inc.Pfizer Inc. and Teva Pharmaceutical Industries Ltd. held a high market position in 2020.

A. On the basis of therapy, the medication segment was the major shareholder 2020, as various therapies were used as supportive treatment for lung injury. Depending on injury type, the direct injury acquired the largest share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to rise in incidence of pulmonary infections worldwide.

A. Rise in prevalence of lung-related diseases and increase in geriatric population. Furthermore, increase in awareness related to treatment of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is expected to notably contribute toward the growth of the global market.

A. Asia-Pacific accounted for the largest share of the global lung injury market in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to the presence of large population base, increase in awareness associated with lung injury treatment, and rise in healthcare expenditure.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Oral Cancer Treatment Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers